Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 5Phase 1/2 4Phase 3 2Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer 1

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9Trastuzumab 8anlotinib 7Injections 7Rituximab 6venetoclax 5atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Azacitidine 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × SHR-1701 × Clear all
NCT05149807 2025-08-20

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2/3 Terminated
81 enrolled
Gastrointestinal

Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡